加科思-B(01167)今日盘中大幅上涨5.35%，引起市场关注。
消息面上，公司核心管线Pan-KRAS抑制剂JAB-23E73披露了积极的临床数据。在一期研究中，该药物在可评估的13例KRAS突变胰腺癌患者中，客观缓解率(ORR)达到38.5%，疾病控制率(DCR)为84.6%，且安全性表现优异，三级治疗相关不良事件发生率仅为11.9%，显著低于同类产品。此外，中国药监局已批准其联合化疗用于KRAS突变胰腺癌一线治疗的临床试验。
与此同时，公司此前公布了2025年度业绩，亏损收窄至1.46亿元人民币，并与阿斯利康就JAB-23E73达成了总潜在价值最高达19.15亿美元的重大合作协议，包括1亿美元预付款。公司首个商业化产品戈来雷塞也已在中国获批上市并纳入医保。这些积极的研发进展和商业化里程碑共同推动了股价上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.